PPBT (Purple Biotech) Other Stockholders Equity: $27.28 Mil (As of Mar. 2026)


PPBT Purple Biotech Ltd PPBT
19 GF Score
Price $1.59
! 2 Warning Signs
View Full Analysis

What is Purple Biotech Other Stockholders Equity?

Purple Biotech PPBT -6.47% 19 Other Stockholders Equity is $27.28 Mil as of Mar. 2026. GuruFocus rates PPBT with a GF Score™ of 19/100. The stock has 2 warning signs investors should review.

Purple Biotech's Other Stockholders Equity for the quarter that ended in Mar. 2026 was $27.28 Mil.

Purple Biotech's quarterly Other Stockholders Equity declined from Sep. 2025 ($28.58 Mil) to Dec. 2025 ($28.41 Mil) and declined from Dec. 2025 ($28.41 Mil) to Mar. 2026 ($27.28 Mil).

Purple Biotech's annual Other Stockholders Equity declined from Dec. 2023 ($38.56 Mil) to Dec. 2024 ($30.02 Mil) and declined from Dec. 2024 ($30.02 Mil) to Dec. 2025 ($28.41 Mil).

Purple Biotech Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Purple Biotech's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Purple Biotech Other Stockholders Equity Chart

Purple Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 36.88 38.18 38.56 30.02 28.41

Purple Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.96 28.51 28.58 28.41 27.28
PPBT
19GF Score
Purple Biotech Ltd PPBT
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Purple Biotech Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $27.28 Mil mean?
Purple Biotech (PPBT) has a Other Stockholders Equity of $27.28 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Purple Biotech and its competitors.
Is Purple Biotech's Other Stockholders Equity too high?
Purple Biotech's current Other Stockholders Equity is $27.28 Mil. Overall, Purple Biotech has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Purple Biotech's Other Stockholders Equity compare to VRTX and REGN?
Purple Biotech's Other Stockholders Equity of $27.28 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Purple Biotech and its competitors. Purple Biotech's current Other Stockholders Equity is $27.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Purple Biotech stock overvalued right now?
Purple Biotech (PPBT) has a current Other Stockholders Equity of $27.28 Mil. The current Other Stockholders Equity is $27.28 Mil. Purple Biotech's overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Purple Biotech (PPBT), the current Other Stockholders Equity is $27.28 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Purple Biotech Business Description

Other Exchanges PPBT:Israel
Address 4 Oppenheimer Street, Science Park, Rehovot, ISR, 7670104
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.
19GF Score

Get the complete analysis for PPBT

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.59
Price